Internal Reference Number: FOI_7304
Date Request Received: 12/07/2023 00:00:00
Date Request Replied To: 02/08/2023 00:00:00
This response was sent via: By Email
Request Summary: Incidence and treatment of Colorectal Cancer
Request Category: Companies
| Question Number 1: In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents? • Aflibercept • Bevacizumab • Capecitabine • CAPIRI • CAPOX (XELOX) • Cetuximab in combination with FOLFIRI/FOLFOX • Cetuximab not in combination with FOLFIRI or FOLFOX • Irinotecan only • FOLFIRI • FOLFOX • Fluorouracil (5FU) only • Oxaliplatin only • Nivolumab • Panitumumab in combination with FOLFIRI/FOLFOX • Panitumumab not in combination with FOLFIRI or FOLFOX • Pembrolizumab • Raltitrexed • Ramucirumab • Regorafenib • Tegafur + Uracil • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: • Aflibercept0 • Bevacizumab 0 • Capecitabine 5 • CAPIRI 0 • CAPOX (XELOX) 20 • Cetuximab in combination with FOLFIRI/FOLFOX 0 • Cetuximab not in combination with FOLFIRI or FOLFOX 0 • Irinotecan only 0 • FOLFIRI 6 • FOLFOX 7 • Fluorouracil (5FU) only 0 • Oxaliplatin only 0 • Nivolumab 0 • Panitumumab in combination with FOLFIRI/FOLFOX <5 • Panitumumab not in combination with FOLFIRI or FOLFOX 0 • Pembrolizumab <5 • Raltitrexed 0 • Ramucirumab 0 • Regorafenib <5 • Tegafur + Uracil 0 • Any other systemic anti-cancer therapy 5 • Palliative care only unable to answer | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
